Metformin counters oxidative stress and mitigates adverse effects of radiation exposure: An overview

Karmanova, E. E.; Chernikov, A. V.; Usacheva, Anna; Иванов, В. Э.; Брусков, В. И.

doi:10.1111/fcp.12884

Cited by 3 publications

(2 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both experimental and clinical data indicated that metformin, the primary oral antihyperglycemic agent with pharmacological adenosine 5' monophosphateactivated protein kinase (AMPK) activation, could improve the cardiometabolic status in populations with obesity, diabetes, or psychiatric disorders [8]. This improvement was attributed to mechanisms including oxidative stress inhibition and redox rebalance [9][10][11]. To date, scarce studies have investigated the correlations of metformin use with CMD risk and CMDrelated mortality in patients with cancer.…”

Section: Introductionmentioning

confidence: 99%

Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study

Li,

Liu,

et al. 2024

BMC Med

View full text Add to dashboard Cite

Background In the USA, the prolonged effective survival of cancer population has brought significant attention to the rising risk of cardiometabolic morbidity and mortality in this population. This heightened risk underscores the urgent need for research into effective pharmacological interventions for cancer survivors. Notably, metformin, a well-known metabolic regulator with pleiotropic effects, has shown protective effects against cardiometabolic disorders in diabetic individuals. Despite these promising indications, evidence supporting its efficacy in improving cardiometabolic outcomes in cancer survivors remains scarce. Methods A prospective cohort was established using a nationally representative sample of cancer survivors enrolled in the US National Health and Nutrition Examination Survey (NHANES), spanning 2003 to 2018. Outcomes were derived from patient interviews, physical examinations, and public-access linked mortality archives up to 2019. The Oxidative Balance Score was utilized to assess participants’ levels of oxidative stress. To evaluate the correlations between metformin use and the risk of cardiometabolic diseases and related mortality, survival analysis of cardiometabolic mortality was performed by Cox proportional hazards model, and cross-sectional analysis of cardiometabolic diseases outcomes was performed using logistic regression models. Interaction analyses were conducted to explore the specific pharmacological mechanism of metformin. Results Among 3995 cancer survivors (weighted population, 21,671,061, weighted mean [SE] age, 62.62 [0.33] years; 2119 [53.04%] females; 2727 [68.26%] Non-Hispanic White individuals), 448 reported metformin usage. During the follow-up period of up to 17 years (median, 6.42 years), there were 1233 recorded deaths, including 481 deaths from cardiometabolic causes. Multivariable models indicated that metformin use was associated with a lower risk of all-cause (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.47–0.81) and cardiometabolic (HR, 0.65; 95% CI, 0.44–0.97) mortality compared with metformin nonusers. Metformin use was also correlated with a lower risk of total cardiovascular disease (odds ratio [OR], 0.41; 95% CI, 0.28–0.59), stroke (OR, 0.44; 95% CI, 0.26–0.74), hypertension (OR, 0.27; 95% CI, 0.14–0.52), and coronary heart disease (OR, 0.41; 95% CI, 0.21–0.78). The observed inverse associations were consistent across subgroup analyses in four specific cancer populations identified as cardiometabolic high-risk groups. Interaction analyses suggested that metformin use as compared to non-use may counter-balance oxidative stress. Conclusions In this cohort study involving a nationally representative population of US cancer survivors, metformin use was significantly correlated with a lower risk of cardiometabolic diseases, all-cause mortality, and cardiometabolic mortality.

show abstract

Section: Introductionmentioning

confidence: 99%

Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study

Li,

Liu,

et al. 2024

BMC Med

View full text Add to dashboard Cite

show abstract

“…Metformin is an antidiabetic drug that shows redox‐modulating effects and addresses numerous ailments linked with oxidative stress, and can chelate polyvalent metal ions, reduce oxidative stress, and mitigate toxicity (Karmanova et al, 2023 ). Metformin, clomiphene citrate, and tamoxifen are commonly prescribed for PCOS.…”

Section: Introductionmentioning

confidence: 99%

Assessment of hepatoprotective, nephroprotective efficacy, and antioxidative potential of Moringa oleifera leaf powder and ethanolic extract against PCOS‐induced female albino mice (Mus Musculus)

Khalid,

Arshad,

Raza

et al. 2023

Food Science & Nutrition

View full text Add to dashboard Cite

Moringa oleifera is a medicinal plant that has anti‐inflammatory, antihypertensive, antidiabetic, tissue‐protective, and antioxidant activities. Here, we evaluated the protective effect of M. oleifera leaf powder (MoLP) and 70% ethanol M. oleifera leaf extract (MoLE) on mitigating polycystic ovary syndrome (PCOS)‐induced liver and kidney dysfunction via regulating oxidative stress in female albino mice (Mus musculus). The efficacy of M. oleifera was compared with metformin (standard medicine used to treat infertility in women). PCOS was induced by intramuscular injection of testosterone enanthate at 1.0 mg/100 g BW for 35 days. PCOS‐induced mice were treated with MoLP (250 and 500 mg/Kg), MoLE (250 and 500 mg/kg), and metformin (250 mg/kg) orally for 14 days. Renal function test (RFT), liver function test (LFT), and oxidative stress biomarker malondialdehyde (MDA) were quantified in serum at 0, 7, and 14 days of intervention. Mice treated with M. oleifera and metformin showed a significant decrease (p < .001) in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphate (ALP), total bilirubin, urea, creatinine, and a significant increase (p < .001) in total protein, albumin, globulin, and albumin/globulin (A/G) ratio. Oxidative stress decreased significantly (p = .00) with respect to treatments, exposure days, and their interaction in metformin and all M. oleifera‐treated groups. M. oleifera leaf powder and extract reduce oxidative stress and enhance nephron‐hepatic activity in PCOS‐induced female albino mice.

show abstract

Protective effects of pioglitazone in renal ischemia–reperfusion injury (RIRI): focus on oxidative stress and inflammation

Golmohammadi,

Ivraghi,

Hasan

et al. 2024

Clin Exp Nephrol

View full text Add to dashboard Cite

Metformin counters oxidative stress and mitigates adverse effects of radiation exposure: An overview

Cited by 3 publications

References 161 publications

Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study

Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study

Assessment of hepatoprotective, nephroprotective efficacy, and antioxidative potential of Moringa oleifera leaf powder and ethanolic extract against PCOS‐induced female albino mice (Mus Musculus)

Protective effects of pioglitazone in renal ischemia–reperfusion injury (RIRI): focus on oxidative stress and inflammation

Contact Info

Product

Resources

About